Thomas J. Maimone

This paper develops a stereoselective covalent inhibitor of PAX8, a key ovarian cancer driver, showing its ability to reduce PAX8 abundance and suppress its transcriptional program.

This paper identifies a sulfinyl aziridine compound that selectively degrades MYC by targeting specific residues in its intrinsically disordered regions, demonstrating the potential of chiral small molecules for targeting undruggable proteins.